期刊文献+

10例肺炎型肺癌的诊治体会 被引量:2

The Experience of Diagnosis and Treatment of 10 Cases With Pneumonic-tupe Lung Cancer
下载PDF
导出
摘要 目的探讨肺炎型肺癌的临床特征,提高认识,减少误诊。方法分析10例肺炎型肺癌患者的临床表现、影像学表现及诊治过程。结果肺炎型肺癌临床可表现为发热,咳嗽,咳痰,呼吸困难;胸部CT表现为大片状模糊阴影;抗感染、抗结核治疗无效。经3~38个月随访,其中有8例患者1年内均死于呼吸衰竭,1例患者生存期长达30个月(口服分子靶向药物),1例术后患者目前身体状态好,无复发和转移。肺炎型肺癌病理类型以腺癌为主,发现时大部分发展为晚期,治疗以化疗和分子靶向治疗为主,如有EGFR基因突变,生存期可达30个月以上。结论肺炎型肺癌极易误诊为肺炎,临床医生应该提高对本病的认识。 Objective To investigate the clinical manifestations of pneumonic-type lung carcinoma,in order to improve the understanding of the clinical features of pneumonic-type lung carcinoma and decrease the rate of misdiagnosis.Methods The clinical manifestation,the imaging characteristics,the process of diagnosis and treatment of the ten cases pneumonia styled lung cancer were reviewed and analyzed.Results Clinical manifestation of pneumonia styled lung cancer goes like:fever,exspectoration,dyspnea;thoracic CT showing big blurred shadow;anti-infection and anti-tuberculosis treatment was useless.After 3 to 38 months,8 patients died of respiratory failure in 1 years,1 patients had a survival period of up to 30 months(oral molecular targeting drugs),and 1 patients was now in good physical condition without recurrence and metastasis.The pathological types of lung cancer are mainly adenocarcinoma,and most of them develop late,the treatment is mainly chemotherapy and molecular targeted therapy,and if EGFR gene mutation,the survival period can reach more than 30 months.Conclusion It is extremely possible to diagnose pneumonia styled lung cancer as pneumonia,and clinicians should enhance kownledge of this disease.
作者 徐刚 XU Gang(Respiratory Medical Department,General Hospital of Nongken Bureau in Heilongjiang Province,Harbin Heilongjiang 150088,China)
出处 《中国卫生标准管理》 2018年第8期31-33,共3页 China Health Standard Management
关键词 肺癌 肺炎 误诊 病理类型 影像学表现 预后 lung carcinoma pneumonia misdiagnosis pathological type the imaging characteristics prognosis
  • 相关文献

参考文献6

二级参考文献56

  • 1李玉昕.不同年龄段肺炎型肺癌患者的高分辨率CT表现[J].中外健康文摘,2013,(35):78-79.
  • 2杨树林.肺炎型肺癌的特征与病理对照及诊断[J].中外健康文摘,2013,1O(8):213.
  • 3Cohen MH,Johnson JR,Wang YC,et al.FDA drug approval summary:peme trexed for injection(Alimta) for the treatment of non- small cell lung cancer [J]. Oncologist,2005,10(6):363-368.
  • 4Manegold C,Gatzemeier U,von Pawel J,et al. Front-line treatment of advanced non-small-cell lung cancer with MTA and cisplatin:a muhicenter phasel II trial [J].Ann Oncol,2000, 11 (4):435-440.
  • 5Shepherd FA,Dancey J,Amold A,et al.Phase II study of pemetrexed disodium,a muhitargeted antifolate,and cisplatin as flint-line therapy in patients with advanced non-small-cell lung carcinoma[J]. Cancer,2001,92( 3 ):595-600.
  • 6Scagliotti GV,Parik K, Patil S,et al.Survival without toxicity for Cisplatin plus Pemetrexed versus Cisplatin plus Gemcitabine in chemonaive patients with advanced non-small-cell lung eaneer:arisk-benefit analysis of a large phase III study [J].Eur J Cancer,2009,45 ( 13):2298-2303.
  • 7Gronberg BH,Bremnes RM,Flotten O,et al.Phase III study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer[J].CIin Oncol,2009,27(19):3217-3224.
  • 8Klein R.Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small-cell lung cancer[J].J Thorac Oncol,2009,4 (11):1404-1414.
  • 9Akata S,Fukushima A,KaKizaki D,et al. Cq" scanning of bron- chioloalveolar carcinoma: specific appearances [J]. Lung Cancer, 1995,12(3) :221-230.
  • 10Jung JI,Kim H,Park SH,et al. CT differentiation of pneumonie- type bronchioloalveolar cell carcinoma and infectious pneumonia [Jl. Br J Radiol,2001,74:490-494.

共引文献39

同被引文献22

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部